News and Media
News and Media
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
August 27, 2020
Onxeo Announces its Financial Agenda for 2020
December 9, 2019
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
November 13, 2019
Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.
November 5, 2019
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
November 4, 2019
Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000
October 17, 2019
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2019
Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
October 14, 2019
Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy
September 18, 2019
Onxeo to Attend Key Investor and Scientific Conferences
September 11, 2019
Publication of the 2019 Half-Yearly Financial Report
July 31, 2019
Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update
July 25, 2019
The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation
July 1, 2019
Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase
June 20, 2019
Onxeo renews its equity financing line with Nice & Green as part of the financing of its business and strategic activities
June 7, 2019
Press Release Signup
Subscribe to receive our Press Releases when they come out.
